Drug intelligence / Profile preview

Compound 11a

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

Compound 11a is a potent and selective small molecule antagonist of the NR1/2B subtype of N-methyl-D-aspartate (NMDA) receptors. It has demonstrated the ability to potentiate the effects of L-DOPA in a rat model of Parkinson's disease when administered orally.

Other names: NR1/2B antagonist 11a

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on Compound 11a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Compound 11a.

Explore the full profile